Swedish biotech Calliditas is going all-in when it comes to firsts: After getting the first drug specifically approved for immunoglobulin A (IgA) nephropathy last year, it’s now running the first ...

Calliditas Therapeutics’ slimmed-down, truncated and rethought primary biliary cholangitis (PBC) drug has hit its primary endpoint. But the biotech only saw a positive trend on liver stiffness and ...

Calliditas Therapeutics' CALT shares were up almost 7% on Aug 18, as the FDA accepted the submission of a supplement new drug application (sNDA) seeking to convert accelerated approval of Tarpeyo ...

"Calliditas will continue to build and benefit from a broad and highly competent senior team which operates in an integrated manner. As the company has grown there is now need for a smaller and more ...

Swedish biotech Calliditas has announced plans to file its rare disease drug Nefecon with the FDA early next year following positive results from a phase 3 clinical trial. The company has been ...

Calliditas has filed to raise SEK 650 million ($75 million) through an IPO in Sweden. The financing will set Calliditas up to start enrolling autoimmune kidney disease patients in a pivotal trial ...

STOCKHOLM, Oct. 7, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company now controls 100% of the share capital of ...

STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced publication in The Lancet of the full data from the Phase 3 NefIgArd ...

STOCKHOLM, March 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a New Drug Application (NDA) to the U.S.

Japanese chemical company Asahi Kasei Corporation made a $1.1 billion (SEK 11.164 billion) takeover bid for Swedish pharmaceutical company Calliditas Therapeutics AB (NASDAQ:CALT). The deal offers 208 ...

Japanese company Asahi Kasei has made a public cash offer for the acquisition of all shares in the Swedish drugmaker Calliditas for Skr11.16bn ($1.04bn). The deal would involve the purchase of ...

STOCKHOLM, Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 ...